Comparative Pharmacology
Head-to-head clinical analysis: ERYTHRA DERM versus PROKLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHRA DERM versus PROKLAR.
ERYTHRA-DERM vs PROKLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. It also exhibits anti-inflammatory and immunomodulatory effects, reducing neutrophil chemotaxis and bacterial lipase production.
PROKLAR (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Apply a thin layer to the affected area(s) twice daily. For topical use only. Adult dose is 2% solution or ointment.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life of 2-4 hours; prolonged to 5-6 hours in hepatic impairment.
Terminal elimination half-life: 2-4 hours (prolonged to 6-8 hours in hepatic impairment); context: requires q8-12h dosing in normal renal function
Primarily biliary fecal elimination (60-70%); renal excretion of unchanged drug <15%.
Renal: 20-30% unchanged; fecal: 15-30%; biliary: 5-10%; total renal excretion of metabolites: ~70%
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic